Navigation Links
Byetta Lawsuit News: Woman Alleges Her Thyroid Cancer Is Linked to Byetta Use, Rottenstein Law Group LLP Reports
Date:5/13/2013

(PRWEB) May 13, 2013

On May 9 a woman filed a lawsuit against drug makers Amylin Pharmaceuticals and Eli Lilly in federal court, alleging that the companies failed to adequately warn her about type 2 diabetes drug Byetta’s link to thyroid cancer, according to court documents for Childress v. Amylin Pharmaceuticals LLC, et al., No. 3:13-1114 (U.S. District Court for the Southern District of California). The Rottenstein Law Group LLP maintains a Byetta Lawsuits Center at http://www.byettalawsuits.us, which features comprehensive information about the drug and steps that need to be taken to file a lawsuit.

Elizabeth Childress was prescribed Byetta in January 2007 to treat her type 2 diabetes, and continued to take it through August of that year, according to court documents. In May 2011 she was diagnosed with thyroid cancer and attributes it to her use of Byetta, a drug that has also been linked to both thyroid cancer and pancreatic cancer in women.* Childress alleges that the drug makers were aware of the risks but did not notify patients of them.

“It is important that the drug makers are held accountable, if the allegations are true,” said Rochelle Rottenstein, principal of the Rottenstein Law Group LLP.

At its Byetta Lawsuits Center, the Rottenstein Law Group LLP provides more information on the several alleged Byetta side effects, including kidney failure and chronic headaches, in addition to the cancer risks.

*fda.gov/Drugs/DrugSafety/ucm343187.htm

For the latest news on defective medications and medical devices and related lawsuits, visit the Rottenstein Law Group LLP’s Injury Lawyer Newswire at http://www.injurylawyernewswire.com. Readers can subscribe to the news site’s stories and videos to stay on top of personal injury news.

About THE ROTTENSTEIN LAW GROUP LLP
The Rottenstein Law Group LLP is a New York-based firm that represents clients nationwide in mass tort actions. The firm was founded by Rochelle Rottenstein, who has more than two decades of experience as a lawyer, to represent clients hurt by defective medical devices and medications. (Attorney advertising. Prior results do not guarantee a similar outcome.)

Contact:
The Rottenstein Law Group LLP
Rochelle Rottenstein, Esq.
321 W. 44th Street
# 804
New York NY 10036
(212) 933-9500 (office phone)
(212) 933-9980 (facsimile)
rochelle (at) rotlaw (dot) com

                            ###

Read the full story at http://www.prweb.com/releases/byetta-diabetes/byetta-side-effects/prweb10729549.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. DrugRisk Update: New Study Warns of Cancer in Byetta Side Effects
2. Pancreatic Cancer Correlation to Type 2 Diabetes Drugs Januvia and Byetta, New Studies Find Possible Connection
3. DrugRisk Announces Launch of Byetta Cancer Resource Center
4. Byetta Pancreatic Cancer Allegation Lawsuits Offered through Resource4thePeople
5. d'Oliveira & Associates Releases New Byetta Infographic on Potential Kidney and Pancreas Health Risks Associated with the Drug
6. Transvaginal Mesh Lawsuit News: Bernstein Liebhard LLP Notes Order Reopening Discovery in Federal C.R. Bard Vaginal Mesh Litigation
7. Vaginal Mesh Lawyers at Bernstein Liebhard LLP Note Issuance of New Order in Federal Pelvic Mesh Litigation for American Medical Systems Lawsuits
8. Update on Pradaxa Internal Bleeding Problem Allegations Lawsuits; Resource4thePeople Reports Bellwether Trial Dates Scheduled
9. Imprelis Lawsuit Filed by Wright & Schulte LLC on Behalf of Multiple Lawn Care Companies and Property Owners Who Allege Imprelis Use Caused Extensive Tree Damage
10. Alleged Bard IVC Filter Failure Lawsuits Update: Resource4thePeople Reports New Cases Continue To Be Filed
11. Da Vinci Robotic Surgery Lawsuit: Parker Waichman LLP Reacts to a Training Specialist Who Said She Taught Doctors How to Use the Robot—Not Operate on Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... "FCPX editors can now reveal their media with ... X," said Christina Austin - CEO of Pixel Film Studios. , ProSlice Color ... users can now reveal the media of their split screens with growing colorful ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... patient payment industry today announced its strategic partnership with Connance, a healthcare ... , The two companies’ proven, proprietary technology combine to provide health systems, ...
(Date:6/27/2016)... Park, KS (PRWEB) , ... June 27, 2016 , ... ... in retailers of Eyeglasses . , Millions of individuals in the United States ... eyeglasses have become a way to both correct vision and make a fashion statement. ...
(Date:6/26/2016)... Battle Creek, Michigan (PRWEB) , ... June 26, 2016 , ... ... abuse, joined as sponsor of the 2016 Cereal Festival and World’s Longest Breakfast Table ... held in honor of the city’s history as home to some of the world’s ...
(Date:6/26/2016)... ... ... PawPaws brand pet supplements owned by Whole Health Supply is ... of felines. The formula is all-natural and is made from Chinese herbs that have ... Kidney Support Supplement Soft Chews are Astragalus Root Extract and Rehmannia Root Extract ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016 ... appointment of Dr. Edward Futcher to ... Director, effective June 23, 2016.Dr. Futcher was also ... and Governance Committees.  As a non-executive member of ... expertise and strategic counsel to VolitionRx in connection ...
(Date:6/23/2016)... June 23, 2016 Research and ... Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), ... Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is projected ... CAGR of 6.1% in the forecast period 2016 to ...
(Date:6/23/2016)... 23, 2016 Research and Markets has ... 52" report to their offering. ... creates a favourable commercial environment for MedImmune to enter. The ... that will serve to drive considerable growth for effective anti-influenza ... to cap sales considerably, but development is still in its ...
Breaking Medicine Technology: